AI Article Synopsis
- Researchers studied how special cells called ABCB5 MSCs affect calcium levels in blood vessel cells when there isn't enough oxygen (called hypoxia).
- They did experiments in the lab and in mice to see how these MSCs help fix calcium problems, improve cell growth, and help form new blood vessels.
- The results showed that ABCB5 MSCs can help restore healthy calcium levels, which could help improve blood flow and healing in low-oxygen conditions.
Article Abstract
Background: Hypoxia in ischemic disease impairs Ca homeostasis and may promote angiogenesis. The therapeutic efficacy of mesenchymal stromal cells (MSCs) in peripheral arterial occlusive disease is well established, yet its influence on cellular Ca homeostasis remains to be elucidated. We addressed the influence of ATP-binding cassette subfamily B member 5 positive mesenchymal stromal cells (ABCB5 MSCs) on Ca homeostasis in hypoxic human umbilical vein endothelial cells (HUVECs) in vitro and in vivo.
Methods: Hypoxia was induced in HUVECs by Cobalt (II) chloride (CoCl) or Deferoxamine (DFO). Dynamic changes in the cytosolic- and endoplasmic reticulum (ER) Ca and changes in reactive oxygen species were assessed by appropriate fluorescence-based sensors. Metabolic activity, cell migration, and tube formation were assessed by standard assays. Acute-on-chronic ischemia in Apolipoprotein E knock-out (ApoE) mice was performed by double ligation of the right femoral artery (DFLA). ABCB5 MSC cells were injected into the ischemic limb. Functional recovery after DFLA and histology of gastrocnemius and aorta were assessed.
Results: Hypoxia-induced impairment of cytosolic and ER Ca were restored by ABCB5 MSCs or their conditioned medium. Similar was found for changes in intracellular ROS production, metabolic activity, migratory ability and tube formation. The restoration was paralleled by an increased expression of the Ca transporter Sarco-/endoplasmic reticulum ATPase 2a (SERCA2a) and the phosphorylation of Phospholamban (PLN). In acute-on-chronic ischemia, ABCB5 MSCs treated mice showed a higher microvascular density, increased SERCA2a expression and PLN phosphorylation relative to untreated controls.
Conclusions: ABCB5 MSCs therapy can restore cellular Ca homeostasis, which may beneficially affect the angiogenic function of endothelial cells under hypoxia in vitro and in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912525 | PMC |
| http://dx.doi.org/10.1186/s13287-022-03228-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potency assay to predict the anti-inflammatory capacity of a cell therapy product for macrophage-driven diseases: overcoming the challenges of assay development and validation.
Cytotherapy
May 2024
RHEACELL GmbH & Co. KG, Heidelberg, Germany. Electronic address:
Article Synopsis
- * An in vitro model was created by coculturing skin-derived ABCB5 MSCs with M1-polarized macrophages to measure the secretion of interleukin 1 receptor antagonist (IL-1RA) as a marker of anti-inflammatory potency, using an enzyme-linked immunosorbent assay for analysis.
- * The study successfully established a reproducible assay that confirms effective MSC stimulation in an inflammatory environment, demonstrating low failure rates in product testing and providing useful data for clinical efficacy comparisons.
Clinical-grade human skin-derived ABCB5+ mesenchymal stromal cells exert anti-apoptotic and anti-inflammatory effects and modulate mRNA expression in a cisplatin-induced kidney injury murine model.
Front Immunol
January 2024
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.
Article Synopsis
- Acute kidney injury (AKI) is a quick decline in kidney function, often triggered by the cancer drug cisplatin, and current treatments to reverse it are lacking effectiveness.
- Mesenchymal stromal cells (MSCs), particularly those expressing ABCB5, have shown promise in treating inflammatory conditions and improving kidney function in preclinical studies.
- In an experiment on rats, ABCB5+ MSCs effectively reduced cell death in kidney cells, inhibited immune cell proliferation, and modulated inflammation responses, indicating their potential as a therapy for cisplatin-induced AKI.
Drug Regulatory-Compliant Validation of a qPCR Assay for Bioanalysis Studies of a Cell Therapy Product with a Special Focus on Matrix Interferences in a Wide Range of Organ Tissues.
Cells
July 2023
RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany.
Article Synopsis
- qPCR is an important method for studying how human cell-based therapies behave in immunodeficient mice post-xenotransplantation, but tissue differences in the host can skew results if not properly accounted for.
- The authors developed and validated a TaqMan qPCR assay to accurately measure mesenchymal stromal cells in the lab, focusing on a specific DNA sequence that helps identify human cells.
- Their findings showed that matrix effects varied significantly among 14 mouse tissues, suggesting that systematic adjustments for these effects should be made during data analysis to ensure accurate cell quantification.
Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5 Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa.
Cells
May 2023
RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany.
Article Synopsis
- - Recessive dystrophic epidermolysis (RDEB) is a genetic skin disorder that causes painful blisters and chronic wounds, with no current cure available.
- - A clinical trial treated 14 RDEB patients with three infusions of ABCB5 mesenchymal stromal cells (MSCs), leading to improved healing of existing wounds and a decrease in the formation of new wounds.
- - A detailed analysis indicated that the newly formed wounds healed more quickly and stayed closed longer, suggesting that ABCB5 MSCs may help stabilize the skin and could benefit RDEB treatment with ongoing therapy.
Expansion and characterization of human limbus-derived stromal/mesenchymal stem cells in xeno-free medium for therapeutic applications.
Stem Cell Res Ther
April 2023
Centre for Ocular Regeneration, Prof. Brien Holden Eye Research Centre, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Background: Mesenchymal stem cells (MSCs) have been proven to prevent and clear corneal scarring and limbal stem cell deficiency. However, using animal-derived serum in a culture medium raises the ethical and regulatory bar. This study aims to expand and characterize human limbus-derived stromal/mesenchymal stem cells (hLMSCs) for the first time in vitro in the xeno-free medium.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!